Document is current
Any future updates will be listed below
-
Authors
Rosenzweig, Neta https://orcid.org/0000-0002-8668-6466
Kleemann, Kilian L.
Rust, Thomas https://orcid.org/0000-0003-2000-8141
Carpenter, Madison
Grucci, Madeline
Aronchik, Michael
Brouwer, Nieske
Valenbreder, Isabel https://orcid.org/0009-0006-9583-9520
Cooper-Hohn, Joya
Iyer, Malvika
Krishnan, Rajesh K.
Sivanathan, Kisha N.
Brandão, Wesley
Yahya, Taha
Durao, Ana
Yin, Zhuoran
Chadarevian, Jean Paul
Properzi, Michael J.
Nowarski, Roni
Davtyan, Hayk https://orcid.org/0000-0001-8554-6456
Weiner, Howard L.
Blurton-Jones, Mathew https://orcid.org/0000-0002-7770-7157
Yang, Hyun-Sik https://orcid.org/0000-0002-8318-0443
Eggen, Bart J. L. https://orcid.org/0000-0001-8941-0353
Sperling, Reisa A. https://orcid.org/0000-0003-1535-6133
Butovsky, Oleg https://orcid.org/0000-0003-0186-8867
-
Funding
Funding for this research was provided by:
Cure Alzheimer’s Fund (2022A005899)
BrightFocus Foundation (2020A016806)
Alzheimer’s Association (AARF-21-846786)
- License Information
-
More Information
Article History
Received: 15 September 2023
Accepted: 11 June 2024
First Online: 3 July 2024
Competing interests
: O.B., N.R. and K.L.K. are inventors of a patent licensed by Brigham and Women’s Hospital for the use of IL-17F inhibitors for the treatment of neurodegenerative diseases. O.B. declares collaboration with GSK and Regulus Therapeutics; research funding from Sanofi and GSK; honoraria for lectures; and consultancy for UCB, Camp4, Ono Pharma USA and General Biophysics. All other authors declare no competing interests.
